BOUNDLESS BIO, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
BOUNDLESS BIO, INC. (BOLD) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$23.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-07
- BOUNDLESS BIO, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$23.69M.
- BOUNDLESS BIO, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$13.55M.
- BOUNDLESS BIO, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$13.88M.
- BOUNDLESS BIO, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$15.68M.
- BOUNDLESS BIO, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$58.20M.
- BOUNDLESS BIO, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$65.36M.
- BOUNDLESS BIO, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$49.43M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$23.69M 10-Q · filed 2026-08-07 | -$37.25M derived: sum of 2 quarters · filed 2026-08-07 | ||
| 2026-03-31 | -$13.55M 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | -$58.20M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | -$13.88M 10-Q · filed 2025-11-05 | -$29.55M derived: sum of 2 quarters · filed 2026-08-07 | -$45.31M derived: sum of 3 quarters · filed 2026-08-07 | |
| 2025-06-30 | -$15.68M 10-Q · filed 2026-08-07 | -$31.43M derived: sum of 2 quarters · filed 2026-08-07 | ||
| 2025-03-31 | -$15.76M 10-Q · filed 2026-08-07 | |||
| 2024-12-31 | -$65.36M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | -$16.51M 10-Q · filed 2025-11-05 | -$33.48M derived: sum of 2 quarters · filed 2025-11-05 | -$48.91M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | -$16.98M 10-Q · filed 2025-11-05 | -$32.41M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | -$15.43M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | -$49.43M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | -$13.17M 10-Q · filed 2024-11-07 | -$25.57M derived: sum of 2 quarters · filed 2024-11-07 | -$37.29M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$12.40M 10-Q · filed 2024-11-07 | -$24.12M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | -$11.72M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |